Lifecycle Pharma gets good results with LCP-Tacro

11/7/2007 | Forbes

LCP-Tacro, a potential drug treatment designed to prevent organ rejection after transplant surgery, was successful in Phase I clinical trials, its maker, Lifecycle Pharma AS, said. In the study, the treatment compared favorably to the transplant treatment Advagraf.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN